Search Result for "Prostate Cancer"
Cancer Treatment
Brachytherapy

Brachytherapy, also called internal radiation therapy, can effectively treat certain cancers, such as cervical and prostate cancers, in novel ways. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, you receive care from skilled experts who are leaders in their field. Our experienced radiation oncologists perform intricate brachytherapy procedures with your safety and comfort in mind at all times.

Cancer Treatment
Intensity-Modulated Radiation Therapy (IMRT)

At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our team pioneered the use of intensity-modulated radiation therapy (IMRT) decades ago. Today, our experts use IMRT to treat certain cancers, such as prostate and lung cancers, with incredible precision. IMRT’s increased effectiveness — with fewer side effects — offers new possibilities for what you can do during and after cancer treatment.

Clinical Trial

S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)

This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.

Cancer Treatment
Robotic Surgery

At Mays Cancer Center, home to UT Health San Antonio MD Anderson, our surgical experts have extensive experience with advanced robotic techniques. Robotic surgery helps us safely remove complex cancers while protecting nearby healthy tissues. It provides a high level of precision for delicate regions such as the prostate, genitourinary tract, and head and neck. With robotic techniques, many people experience a faster recovery.

Clinical Trial

An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients with Advanced Systemic Mastocytosis (CTMS# 18-0071)

This is an open-label, single arm, Phase 2 study evaluating the efficacy and safety of avapritinib (BLU-285) in patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive SM (ASM), SM with associated hematologic neoplasm (SM-AHN), and mast cell leukemia (MCL)